Capricor Therapeutics, Inc. (CAPR) shares surged 342.30 percent, rising $21.77 to $28.13 on Wednesday after announcing positive topline data from its pivotal Phase 3 HOPE-3 trial of Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. The study showed statistically significant improvements in both skeletal and cardiac function, reinforcing durability seen in previous HOPE-2 studies.
Capricor is trading at $28.13, compared with a previous close of $6.36 on the Nasdaq. The stock opened at $30.00 and has traded between $21.50 and $40.37 so far today, with volume at 39.80 million shares.
The company's 52-week range is $4.30 to $40.37.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.